Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy

AIDS

Volumn 15, Issue 6, 2001, Pages 717-723

  John, Mina ^a   Moore, Corey B ^a   James, Ian R ^a   Nolan, David ^a   Upton, Richard P ^a   McKinnon, Elizabeth J ^a   Mallal, Simon A ^a,b  

^a MURDOCH UNIVERSITY   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

HAART; Hepatic steatosis; Hyperlactatemia; Lactic acidosis; Lipodystrophy; Mitochondrial toxicity; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Protease inhibitors; Subcutaneous fat wasting

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LACTIC ACID; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CHRONIC DISEASE; DRUG INDUCED DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS INFECTION;

ACIDOSIS, LACTIC; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHRONIC DISEASE; DATA INTERPRETATION, STATISTICAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LACTIC ACID; MALE; MITOCHONDRIA; PREVALENCE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 0035853430     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200104130-00007     Document Type: Article

References (22)

1. A new syndrome of hepatomegaly with severe steatosis in HIV seropositive patients
2. Hepatomegaly and steatosis in HIV infected patients receiving nucleoside analogue antlretroviral therapy
3. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine
4. Hepatic steatosis and lactic acidosis associated with stavudine treatment in a HIV patient: A case report
5. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
6. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study (SHCS)
7. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens
8. Lactic acidosis complicating antiretroviral therapy: Frequency and correlates
9. The occurrence of hyperlactatemia in HIV-infected patients on NRTI treatment
10. Lactic acidosis and other mitochondrial disorders
11. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as a common pathway
12. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
13. NRTI-induced mitochondrial toxicity as an aetiology for fat redistribution syndrome
14. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
15. The Western Australian HIV Cohort Study, Perth, Australia
16. Lactic acidosis
17. Mitochondrial function and exercise capacity in HIV infected patients with lipodystrophy
18. Editorial response: Hyperlactatemia and hepatic steatosis as features of the mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibltors
19. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
20. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
21. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoslde analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome